GlucoTrack, Inc. (GCTK) vs Jupiter Neurosciences, Inc. (JUNS)
A side-by-side comparison of GlucoTrack, Inc. and Jupiter Neurosciences, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
GCTK
GlucoTrack, Inc.
$1.13HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
JUNS
Jupiter Neurosciences, Inc.
$2.86HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — GCTK vs JUNS
growth of $100 · dividends reinvested · last 2yGCTK -100.0% (-98.4%/yr)JUNS -99.4% (-92.3%/yr)JUNS compounded faster over this window
Log scale — wide-divergence pair
GCTK JUNS
GCTK vs JUNS: by the numbers
- •JUNS is the larger company ($1M vs $901902 market cap).
- •Both run net losses; GCTK's is the smaller (0.00% vs -14220.12% net margin).
Metrics side by side
Valuation
| Metric | GCTK | JUNS |
|---|---|---|
| P/S ratio | N/A | 21.43 |
Profitability
| Metric | GCTK | JUNS |
|---|---|---|
| Gross margin | 0.00% | 88.34% |
| Operating margin | 0.00% | -40873.19% |
| Net margin | 0.00% | -14220.12% |
| ROIC | N/A | -709.40% |
Growth (annualized)
| Metric | GCTK | JUNS |
|---|---|---|
| Revenue CAGR (5Y) | N/A | -47.77% |
| Total return CAGR (5Y) | -92.60% | N/A |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.